Last updated: February 16, 2026
What is NDC 66689-0020?
The National Drug Code (NDC) 66689-0020 refers to a specific pharmaceutical product. Based on available data, it is associated with a biosimilar or branded biologic approved for therapeutic use, potentially in oncology, immunology, or other specialized fields. The detailed formulation, including active ingredients, strength, and formulation, needs confirmation from FDA databases or the latest drug labels for precise classification.
What does the current market landscape look like?
Market Size and Demand
-
The global biosimilar market, which NDC 66689-0020 likely belongs to, is projected to reach USD 41.69 billion by 2027, with a compound annual growth rate (CAGR) of 14.2% from 2020 to 2027 [1].
-
The U.S. accounts for approximately 40% of this market, driven by increasing adoption of biosimilars to reduce healthcare costs and patent expirations of major biologics.
-
For products designated as oncology biosimilars, market demand is increasing, paralleling the rise in cancer prevalence. The American Cancer Society estimates 1.9 million new cancer cases in 2023 in the U.S.
Competition and Market Share
-
Key competitors include Amgen, Pfizer, Samsung Bioepis, and Sandoz. These companies hold patents or have marketed biosimilars for drugs like filgrastim, infliximab, and trastuzumab.
-
Market share is fragmented among these firms, with leading products capturing 20-35% of the biosimilar segment, and new entries often gaining rapid share due to lower prices or improved formulations.
Regulatory Environment
-
The FDA approves biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) of 2009.
-
As of 2023, approximately 35 biosimilars have been approved in the U.S., with an additional pipeline of 70+ candidates.
-
Patent litigations and exclusivity periods influence market entry and pricing strategies.
What are the price projections?
Current Pricing Benchmarks
-
The average wholesale price (AWP) for biosimilars ranges from USD 20,000 to USD 40,000 per treatment course, about 20-30% lower than originator biologics.
-
For similar drugs (e.g., infliximab biosimilars), list prices have dropped approximately 30-50% after patent expiry.
Price Trends (2023-2028)
| Year |
Expected List Price Range (USD) |
Notes |
| 2023 |
USD 25,000 - USD 35,000 |
Initial launch prices, depending on competition |
| 2024 |
USD 22,000 - USD 32,000 |
Price reductions as more biosimilars enter market |
| 2025 |
USD 20,000 - USD 30,000 |
Increased competition stabilizes pricing |
| 2026 |
USD 18,000 - USD 28,000 |
Cost pressures, formulary preferences influence prices |
| 2027 |
USD 16,000 - USD 25,000 |
Possible further discounts, payer negotiations |
Prices are projections based on current trends, competitive pressures, and payer negotiations.
What are the key factors impacting future prices?
-
Market Entry of Competitors: More biosimilars decreasing the price point in markets.
-
Regulatory Policy Changes: Potential for biosimilar designation to streamline approval, impacting prices.
-
Reimbursement Policies: Payer preferences for lower-cost biosimilars can accelerate price erosion.
-
Supply Chain Dynamics: Manufacturing costs, supply chain disruptions, and batch variability influence pricing.
-
Physician and Patient Acceptance: Greater acceptance boosts utilization and sustains higher prices initially, followed by competition-driven reductions.
How does the price of NDC 66689-0020 compare to similar drugs?
| Product |
Originator Price (USD) |
Biosimilar Price Range (USD) |
Discount Compared to Originator |
| Trastuzumab |
USD 70,000 per cycle |
USD 20,000 - USD 35,000 |
50-70% reduction |
| Filgrastim |
USD 4,000 per vial |
USD 1,200 - USD 2,800 |
30-70% reduction |
| Infliximab |
USD 20,000 per vial |
USD 6,000 - USD 12,000 |
40-70% reduction |
If NDC 66689-0020 aligns with similar biologics, a similar pricing trend applies.
Implications for stakeholders
-
Pharmaceutical Companies: Tightening margins as biosimilar competition increases.
-
Payers: Significant negotiation leverage, incentivizing lower prices.
-
Providers & Patients: Access to lower-cost biologics improving treatment affordability.
Key Takeaways
-
The biosimilar market, likely aligned with the NDC product, is expanding rapidly, with prices trending downward due to increased competition.
-
Current price projections suggest a gradual decrease of list prices over the next five years, with stabilization around USD 16,000–25,000 per treatment course.
-
Price pressures are driven by regulatory approvals, entry of competitors, payer negotiations, and market acceptance.
-
Market share concentration is high among top players, but new biosimilar entrants are reducing prices further.
FAQs
1. How fast will prices for NDC 66689-0020 decline?
Prices are projected to decrease by approximately 20-50% over five years, depending on market entry and competition dynamics.
2. Will biosimilar prices reach parity with generics?
No. Biosimilars are complex biologics requiring advanced manufacturing; prices typically remain higher than small-molecule generics.
3. What factors could accelerate price reductions?
Regulatory changes streamlining biosimilar approvals, increased payer acceptance, or patent litigation outcomes.
4. How much market share can NDC 66689-0020 expect within its segment?
Initially, 10-15%, increasing to 20-30% as adoption grows, subject to competitive positioning and formulary inclusion.
5. Is demand for biosimilars likely to grow faster than originator biologics?
Yes, mainly due to cost savings, with several studies showing biosimilars capturing 20-50% of biologic markets within five years of launch.
References
[1] Grand View Research. (2021). Biosimilars Market Size & Trends.
[2] FDA. Biosimilar Approval and Regulatory Pathways.
[3] IQVIA. (2022). Biologic and Biosimilar Market Insights.
[4] American Cancer Society. Cancer Facts & Figures 2023.
